New pill shows promise for schizophrenia psychosis

NCT ID NCT01499563

Completed Symptom relief Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during an acute psychotic episode. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control for 28 days. The main goal was to measure changes in symptom severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ITI-007
What this could lead to: If successful, this could lead to a new medication to ease schizophrenia symptoms during acute episodes.
What could go wrong: This is an early phase 2 trial, so results may not confirm effectiveness. The drug could also have side effects or fail to outperform placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Clinical Site

Little Rock, Arkansas, United States
Clinical Site

Garden Grove, California, United States
Clinical Site

Atlanta, Georgia, United States
Clinical Site

Rockville, Maryland, United States
Clinical Site

St Louis, Missouri, United States
Clinical Site

Willingboro, New Jersey, United States
Clinical Site

Philadelphia, Pennsylvania, United States
Clinical Site

Austin, Texas, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.